Feb 22, 2017 · In this study it was hypothesised that N-linked glycosylation might impede the binding of Herceptin to HER2 in breast cancer and alter cancer cell sensitivity to DXR and growth factors.

Nov 7, 2022 · Innovations in pathology, molecular biology and drug development have enabled HER2-positive breast cancer (BC), a historically aggressive subtype, to become one with impressive outcomes.

Currently, the combination of trastuzumab, pertuzumab, and taxane chemotherapy are first-line for HER2+/HR- metastatic breast cancer with potential breakthrough therapies such as trastuzumab-deruxtecan (DS-8201a), margetuximab and tucatinib (ONT-380) on the horizon.

Oct 29, 2017 · We demonstrated that Herceptin could interact with CD16 on NK cells to expand the cytotoxic NK (specifically, CD56 dim) cell population. Additionally, Herceptin increased NK cell migration and cytotoxicity against HER2 + breast cancer cells.

Trastuzumab (herceptin), a humanized, recombinant monoclonal antibody that binds to the extracellular domain of HER2, has been shown to selectively exert anti-tumor effects in cancer models and patients with HER2-amplified breast cancer, and not in tumors with normal HER2 expression [6 – 8].

Aug 9, 2024 · In addition, flow cytometry results revealed that the Arazyme-linker-Herceptin can significantly induce apoptosis in the HER2-overexpressing breast cancer cell line (SKBR3), which was confirmed by Bax upregulation and the decrease in adhesion of …

20 hours ago · Background New data show that not only HER2-overexpressing breast cancer (BC) tumors but also HER2-low tumors, classically considered as HER2-negative, respond to HER2-targeting antibody–drug-conjugates. Our objective was to analyze the prevalence of HER2-low BC in a pooled analysis of contemporary early BC trials and to evaluate its role as a prognostic factor in terms of survival in ...

Since HER2-positive breast cancer is dependent on HER2 gene amplification or overexpression, researchers wanted a way to stop the HER2 protein from exerting its effect on the breast cancer cells. They developed and tested monoclonal antibodies that could recognize and bind to the HER2 protein and hinder its effect on cell growth.

Oct 14, 2014 · We measured the in situ binding kinetics of Herceptin with Her2 in single intact cultured cells and primary cells extracted from breast tumor tissues for the first time with a high...

Feb 8, 2006 · HER-2 is overexpressed in 20–25% of invasive breast cancers and is associated with an aggressive tumor phenotype and reduced survival rate. The HER-2 status of a tumor is the critical determinant of response to the HER-2-targeted antibody Herceptin.